Clinical Trial Update: Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias [Phase 2]

View source ↗

Summary

A Phase 2 trial of fostamatinib for immune-mediated anemia, immune-mediated thrombocytopenia, and chronic graft-versus-host disease after hematopoietic stem cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Immune Mediated Anemia
• Immune Mediated Thrombocytopenia

Drugs mentioned

• Fostamatinib (fostamatinib)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Status: TERMINATED | Results posted: 2025-12-05